The clean GLP tox data derisks VY1706's tau-silencing gene therapy for Alzheimer's and supports clinical entry. Monitor for first-patient-dosed news in 2H 2026 as the next binary catalyst. The stock's $208M market cap suggests a re-rating opportunity if early clinical data mirrors preclinical efficacy.
Price Chart
Executive Summary
Voyager Therapeutics presented favorable GLP toxicology data for VY1706, its tau-silencing gene therapy for Alzheimer's disease, at the AAIC conference. The data showed no adverse findings in NHPs up to the highest dose and up to 75% tau protein lowering in key brain regions through six months. The company previously received FDA IND clearance in June 2026 and plans to begin first-in-human dosing in the second half of 2026.
Key Facts
- Favorable GLP toxicology data for VY1706 presented at AAIC on July 13, 2026
- No adverse CNS, dorsal root ganglia, or peripheral organ findings up to 5 x 10^13 vg/kg in NHPs
- Single IV dose achieved up to 75% lowering of MAPT mRNA and tau protein in key AD brain regions through 6 months
- FDA IND clearance received June 2026
- Multi-site, open-label, dose-escalation clinical trial dosing planned to begin 2H 2026
Financial Impact
No financial figures disclosed in filing
Risk Factors
- Preclinical data may not translate to humans; clinical trial results could disappoint
- First-in-human dosing has not yet commenced
- Forward-looking statements about timing and efficacy are aspirational, not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-082906 |
| Document: 0001104659-26-082906-index-headers.html | 0001104659-26-082906 |
| Document: 0001104659-26-082906-index.html | 0001104659-26-082906 |
| Document: 0001104659-26-082906.txt | 0001104659-26-082906 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $2.02 | awaiting T+60 | — | $1.75 (−13.37%) |
Jul 13, 2026 15w ago | 8-K | $3.24 $2.46 | ▼ −24.07% | ▼ −28.07% | $1.75 (−45.99%) |
Jun 1, 2026 21w ago | 8-K | $3.79 $3.48 | ▼ −8.18% | ▼ −9.41% | $1.75 (−53.83%) |
May 13, 2026 23w ago | Press Release | $4.15 $3.27 | ▼ −21.20% | ▼ −25.64% | $1.75 (−57.83%) |
May 7, 2026 24w ago | Press Release | $4.05 $3.13 | ▼ −22.84% | ▼ −27.68% | $1.75 (−56.79%) |
Apr 27, 2026 26w ago | Press Release | $3.77 $3.09 | ▼ −18.04% | ▼ −22.03% | $1.75 (−53.58%) |
Apr 21, 2026 26w ago | 8-K | $4.14 $3.17 | ▼ −23.43% | ▼ −28.21% | $1.75 (−57.73%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.75 (+53.70%) |
Feb 24, 2026 35w ago | Insider Cluster | $3.78 $3.48 | ▲ +7.94% | ▲ +14.68% | $1.75 (+53.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers